Funding for early-stage
in development at Mount Sinai.
About i3 Genesis
i3 Genesis is an annual funding opportunity for early-stage healthcare technologies with clear potential for commercialization. Part of MSIP’s i3 Family of Funds, this opportunity aims to support and translate innovations by providing up to $50K to achieve value inflection points.
How it Works
Innovators seeking to develop their technology with the potential for commercialization can submit to the i3 Genesis Request for Proposals (RFP) beginning February 27, 2023. Submitted proposals will first be evaluated by a review panel of experts from the MSIP Business Development team in fields including digital health, medical devices, and therapeutics. Some will be selected to pitch their proposal to the review panel during a virtual session conducted via Zoom. Proposals will be judged and scored based on project novelty, feasibility, and market risks against the budget and milestones provided. Awardees will be selected based on recorded scores and recommendations from the review panel. Funding will be disbursed to awardees once the Principal Investigator and their Administrator sign an Informed Participation Letter (IPL). More details will be provided should you be selected for i3 Genesis funding.
Are you interested in being considered for i3 Genesis and have not disclosed the technology? Disclose here.
February 27i3 Genesis RFP period opens
March 27RFP submission due date
Late March to AprilJudging panel reviews submissions
MayPresentations to judging panel and selection of awardees
JuneAwardees notified of selection
July:Project execution begins (pending the IPL signing and finalization of plans and budget)
Eligible applicants must:
Proposals involving Human Subjects or Animal Research require extra steps, such as gaining formal approval from the Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC).
How to Apply
Proposals will be accepted until Monday, March 27 at 5:00pm ET. Submit your proposal via InfoReady at the link below. Please note that applicants must log in by clicking the button in the top right corner of the InfoReady web page.
For more information, please reach out to Louise Lammers, PhD, Director of Business Development, Emerging Assets at email@example.com or William Chiang, PhD, Business Development Consultant, at firstname.lastname@example.org.